Lindsey Shapiro, PhD,  science writer—

Pasithea Therapeutics announced plans to develop a tolerizing vaccine that would treat multiple sclerosis (MS) by “training” the immune system in ways that prevent its damaging attacks. The vaccine will be developed under Pasithea’s new chemical entity development program for MS in collaboration with Hooke…

Changes in the genome of oligodendrocytes were found in DNA regions associated with immune genes and risk mutations linked to multiple sclerosis (MS), a study shows. The changes identified make it possible for these immune genes and MS-associated regions to have an altered expression — meaning being…

A relationship between meat consumption and how it affects gut bacteria, immune cell profiles, and metabolism was identified in people with relapsing-remitting multiple sclerosis (RRMS) participating in a small study. Specifically, a diet rich in meat was associated with a decrease in Bacteriodes thetaiotaomicron, a common gut bacteria that works…

Adverse childhood experiences (ACEs) did not increase the risk of multiple sclerosis (MS) development and were not associated with worse clinical outcomes, a recent study reported. These findings add to the complexity of the potential relationship between ACEs and MS that has emerged across several research studies. “Our primary…

Women with relapsing-remitting multiple sclerosis (RRMS) have more brain lesions and accelerated brain volume loss (BVL) after pregnancy compared with pre-pregnancy measurements, recent data showed. Brain lesions in the early postpartum period — the first months following childbirth — were associated with a higher risk of worsened disability and relapse…

A Kessler Foundation scientist has been awarded nearly $600,000 to support the development and testing of a behavioral therapy intervention aiming to improve quality of life for people with multiple sclerosis (MS). An upcoming clinical trial into the intervention (NCT05195320), expected to begin…

Cyxone will work with a European organization to scale up production of the active ingredient in T20K, its experimental treatment for multiple sclerosis (MS), the company announced. The collaboration, which will cover the development of a new manufacturing method and later the…

Among people with multiple sclerosis (MS), a progressive disease type and the use of anti-CD20 therapies — such as ocrelizumab and rituximab — were associated with an increased risk of death from COVID-19, a new meta-analysis revealed. “We hope that these findings … may help neurologists in optimizing…

Following promising data from the first participant in a special access program that’s testing foralumab nasal spray for secondary progressive multiple sclerosis (SPMS), a second patient has been enrolled in the ongoing evaluation. The first patient in the study, by Tiziana Life Sciences, the nasal spray’s developer, was halfway through…

Ocrevus (ocrelizumab) may be more effective than Gilenya (fingolimod) at preventing relapse in relapsing-remitting multiple sclerosis (RRMS) patients who recently transitioned from Tysabri (natalizumab), according to a new study. Ocrevus is “potentially a better exit strategy than [Gilenya] after [Tysabri] cessation, with an impressive reduction [in] risk…